海澜之家集团股份有限公司 2025 年第一次临时股东会 会 议 资 料 2025 年 10 月 海澜之家集团股份有限公司 2025 年第一次临时股东会材料目录 八、关于提请股东会授权董事会及其授权人士办理与公司发行 H 股股票并 上市有关事项的议案 九、关于公司境外公开发行 H 股股票募集资金使用计划的议案 十四、关于投保董事、高级管理人员及招股说明书责任保险的议案 十五、关于补选公司第九届董事会独立董事的议案 （一）提名穆炯为公司第九届董事会独立董事 （二）提名夏霓为公司第九届董事会独立董事 海澜之家集团股份有限公司 2025 年第一次临时股东会参会须知 为维护投资者的合法权益，确保股东会的正常秩序和议事效率，根据《中华 人民共和国公司法》《中华人民共和国证券法》《上市公司股东会规则》以及《公 司章程》的有关规定，特制订如下参会须知，望出席股东会的全体人员严格遵守： 一、股东会设秘书处，具体负责会议的组织工作并处理相关事宜。 二、股东会期间，全体出席人员应以维护股东的合法权益、确保股东会的正 常秩序和议事效率为原则，自觉履行法定义务。 三、出席股东会的股东，依法享有发言权、表决权等权利。 四、股东会召开期间 ...

Core Viewpoint - The company Kexing Pharmaceutical (688136.SH) announced plans to issue H-shares for a Hong Kong listing, joining a wave of A-share companies pursuing dual listings in Hong Kong, with 25 companies announcing similar plans in September 2023 [1]. Group 1: Company Developments - Kexing Pharmaceutical aims to deepen its "innovation + internationalization" strategy and accelerate overseas business development through the Hong Kong listing [1]. - The company reported a revenue of 700 million yuan in the first half of 2023, a year-on-year decrease of 7.82%, while net profit attributable to shareholders increased significantly by 576.45% to 80.34 million yuan [1]. - The net cash flow from operating activities reached 30 million yuan, a year-on-year increase of approximately 188%, attributed to increased sales collections and reduced operating expenses [2]. Group 2: Research and Development - Kexing Pharmaceutical's innovative drug pipeline has made significant progress, with its interferon α1b inhalation solution included in the list of breakthrough therapies by the National Medical Products Administration [2]. - The company focuses on antiviral, oncology, and immunology research, with R&D investment in the first half of 2023 amounting to approximately 95.97 million yuan, representing 13.70% of total revenue, an increase from 11.52% in the previous year [3]. Group 3: Market Position and Future Outlook - Kexing Pharmaceutical's overseas commercialization platform has expanded to over 40 countries, covering emerging markets with populations over 100 million and GDP rankings in the top thirty [4]. - The company’s product, albumin-bound paclitaxel, has shown significant growth in the European market, with a quarter-on-quarter revenue increase of 35.84% in Q2 2023 [3][4]. - The upcoming Hong Kong listing is expected to help Kexing Pharmaceutical build a dual financing platform, facilitating coordinated development in domestic and international markets [4].

Core Viewpoint - HLA, known as "the men's wardrobe," has announced plans to list on the Hong Kong stock exchange, marking a significant strategic shift as it seeks to expand its international market presence [1][4]. Group 1: Company Performance and Financials - HLA's net profit has not returned to pre-2023 levels since Zhou Licheng took over five years ago, indicating challenges in its business model and market appeal [2][5]. - In the first half of 2025, HLA reported a revenue of 11.566 billion, a year-on-year increase of 1.73%, while net profit decreased by 3.1% to 1.588 billion [10]. - The company's inventory has reached 10.255 billion, a 7.35% increase year-on-year, with an average inventory turnover period of 323 days, indicating potential financial strain [11][13]. Group 2: Market Challenges and Consumer Perception - HLA faces difficulties in appealing to younger consumers, who are increasingly critical of traditional branding narratives and demand more innovative and stylish products [6][7]. - Despite significant advertising expenditures exceeding 2.5 billion over recent years, brand recognition among younger demographics remains limited [8][9]. - The company's business model, which heavily relies on an efficient ODM approach, has not adapted to the evolving preferences of younger consumers, leading to a disconnect in product offerings [8][9]. Group 3: International Expansion Strategy - The primary goal of the Hong Kong listing is to facilitate HLA's global strategy and accelerate overseas business development [15][16]. - HLA has made gradual progress in international markets, with overseas revenue not exceeding 2% of total revenue in recent years, highlighting the need for a more aggressive expansion strategy [21][22]. - The company plans to open its first store in Sydney, Australia, while continuing to deepen its presence in Southeast Asia and exploring markets in Central Asia, the Middle East, and Africa [30][29]. Group 4: Future Challenges and Considerations - HLA's international expansion faces challenges, including differing market conditions, consumer preferences, and competition in developed markets [32][34]. - The company must enhance its product design and development capabilities to compete effectively in international markets, as evidenced by the low R&D expenditure compared to successful global brands [38][36]. - Overall, HLA's future success in global markets will depend on its ability to adapt its business model and product offerings to meet diverse consumer needs [39][40].

Core Insights - The production and demand for suits in China have been declining due to decreased industry prosperity, widespread market saturation, and increased competition from foreign markets. In 2015, the production of suit sets was 594 million pieces, while it is projected to be approximately 165 million pieces by 2024 [1][5]. Industry Overview - Suits, also known as western-style clothing, are characterized by features such as lapels and pockets, and are typically worn in formal settings. They can be categorized by gender, occasion, production process, and button style [2][3]. Current Industry Status - The suit industry in China is experiencing a downward trend in both production and demand. The production of suit sets is expected to decline by 8.61% year-on-year in the first half of 2025 [5][6]. Consumer Demand - There is a growing demand for personalized and comfortable suits, particularly among younger consumers, especially Generation Z. Key preferences include unique styles (53%), body-shaping designs (51%), and high-quality fabrics (48%) [6][7]. Customization Trend - Personalized customization is identified as the future direction of the suit industry, with the high-end custom suit market expected to reach 6.8 billion yuan in 2024 and potentially 8 billion yuan in 2025 [7][11]. Industry Chain - The upstream of the suit industry includes raw materials like cotton, viscose, and wool, while the midstream involves manufacturing. The downstream consists of retail and customization channels, serving consumers through both online and offline methods [8][9]. Historical Development - The suit entered China in 1911 and has evolved from a single style to a diverse range of options, reflecting cultural shifts. The industry is currently transitioning from scale expansion to category restructuring, driven by technological innovation [9][10]. Competitive Landscape - The Chinese suit industry has shifted from OEM production for foreign brands to developing independent brands with advanced technology. The market is competitive, with major players including HLA, Hongdou, Youngor, and Kute Intelligent [10][11]. Future Trends - The demand for suits is expanding beyond business professionals to the general public, with a focus on quality. Future trends include high-end, eco-friendly, and customized products, supported by advancements in smart manufacturing technology [10][11].

Core Viewpoint - The recent trend of A-share companies planning to issue H-shares in Hong Kong reflects a strong demand for internationalization and highlights the deeper logic behind the capital market's opening process [1][2]. Group 1: Companies' Internationalization Strategies - Over 130 A-share companies have announced plans to list in Hong Kong this year, including leading firms like CATL and Heng Rui Medicine, indicating a significant push towards internationalization [1]. - Companies such as CATL aim to seize the global energy transition opportunity, while brands like Wufangzhai and Hailan Home emphasize brand internationalization, showcasing their desire for external market expansion [1]. - Hong Kong is viewed as an optimal "bridge market" for companies aiming for global reach, providing a platform for international branding and market expansion [1]. Group 2: Market Conditions and Regulatory Environment - The advantages of the Hong Kong stock market, including a shorter listing process of 6 to 8 months and flexible refinancing tools, are driving this trend [1]. - Recent regulatory optimizations have lowered listing thresholds and shortened approval cycles, alleviating concerns for companies considering a Hong Kong listing [1]. - The combination of regulatory incentives and companies' strategic needs has created a conducive environment for this wave of listings [1]. Group 3: Challenges and Considerations - Listing in Hong Kong is not without costs; the overall market valuation is relatively low, and companies lacking a stable international investor base may face "price discount" challenges [2]. - Companies will encounter stricter information disclosure and compliance requirements in the international capital market, which may amplify previously manageable issues [2]. - The sustainability of the listing trend is influenced by whether companies have clear international strategies or view it merely as a short-term financing avenue [2].

Investment Rating - The report gives a "Buy" rating for Yanjiang Co., Ltd. (延江股份) based on its expected high growth phase starting in 2025, driven by increased orders and a strong competitive position in the market [18]. Core Insights - The textile and apparel sector has shown weaker performance compared to the market, with the SW textile and apparel index declining by 0.1% from September 29 to September 30, underperforming the SW All A index by 2.1 percentage points [4][5]. - Recent industry data indicates that from January to August, the retail sales of clothing, shoes, and textiles reached 940 billion yuan, a year-on-year increase of 2.9% [4][33]. - The report highlights a significant increase in Australian wool prices, which are expected to benefit New Australia Co., Ltd. (新澳股份) as it capitalizes on the current market cycle [10][11]. Summary by Sections Textile Sector Performance - The textile sector has underperformed the market, with the SW textile and apparel index down 0.1% and the SW apparel and home textiles index flat, both lagging behind the SW All A index [4][5]. - The Australian wool auction prices have reached record highs, with the eastern market composite index rising by 7.7% month-on-month and 41.8% year-on-year, indicating a strong upward trend [10]. Company-Specific Insights - Yanjiang Co., Ltd. is positioned to benefit from the global upgrade of sanitary materials, with expectations of significant order growth in 2025, marking the beginning of a high-growth phase [14][18]. - New Australia Co., Ltd. is expected to see performance improvements due to favorable market conditions and a proactive purchasing strategy, with inventory levels indicating readiness for increased demand [10][11]. Market Trends and Projections - The report notes that the domestic demand recovery is a key theme for 2025, with a focus on high-quality domestic brands that are expected to reverse current challenges [11]. - The report anticipates that the competitive landscape will improve for companies like New Australia Co., Ltd. as many competitors face supply chain challenges due to insufficient inventory [10][11]. Financial Performance and Forecasts - Yanjiang Co., Ltd. is projected to achieve a compound annual growth rate (CAGR) of 94% in net profit from 2025 to 2027, with expected profits of 0.6 billion yuan in 2025, 1.4 billion yuan in 2026, and 2.0 billion yuan in 2027 [18]. - Steady growth is also expected for the medical segment of Steady Medical (稳健医疗), with a projected revenue of 90 billion yuan in 2024, reflecting a compound annual growth rate of 14% over five years [19][20].

Investment Rating - The report gives a "Buy" rating for 延江股份 (Yanjing Co.) based on its expected high growth phase starting in 2025, with projected net profits of 0.6 billion, 1.4 billion, and 2.0 billion yuan for 2025, 2026, and 2027 respectively, indicating a CAGR of +94% [19] Core Views - The textile and apparel sector has shown weaker performance compared to the market, with the SW textile and apparel index declining by 0.1% from September 29 to September 30, underperforming the SW All A index by 2.1 percentage points [5][6] - Recent industry data indicates that from January to August, the total retail sales of clothing, shoes, and textiles reached 940 billion yuan, a year-on-year increase of 2.9% [5][35] - The report highlights a significant increase in Australian wool prices, which are expected to benefit 新澳股份 (New Australia Co.) as it capitalizes on the current wool cycle [11][12] Summary by Sections Textile Sector - The Australian wool auction prices have reached record highs, with the Eastern Market Composite Index increasing by 112 Australian cents per kilogram to 1565 Australian cents per kilogram, marking a 7.7% increase month-on-month and a 41.8% increase year-on-year [11] - 新澳股份 is positioned to benefit from this wool price increase, with expectations of improved performance starting in Q4 2025 due to favorable inventory levels and order trends [11][12] - The report notes that the textile manufacturing sector is currently facing challenges due to U.S. tariffs, but high-quality manufacturers are expected to recover as market conditions improve [12] Apparel Sector - NIKE's FY26Q1 results showed a revenue of 11.7 billion USD, a 1% year-on-year increase, although net profit fell by 31% [13][14] - The report anticipates that NIKE will gradually recover, with significant opportunities arising from its operational improvements [14] - The domestic retail environment is expected to improve, with various initiatives aimed at boosting consumer spending, particularly in the sportswear segment [14] Company Highlights - 延江股份 is recognized for its strong position in the global supply chain for hygiene materials, with a projected high growth phase beginning in 2025 due to increased orders [15][19] - 稳健医疗 (Steady Medical) has shown resilience with a compound annual growth rate of 14% in revenue from 2019 to 2024, and plans to continue focusing on high-quality growth in both its medical and consumer product segments [20][21] - The report emphasizes the importance of brand strength and innovation in driving growth for companies like 稳健医疗, which has successfully navigated multiple economic cycles [20][21]

Core Insights - The article emphasizes the urgency for businesses to embrace AI as 2025 is projected to be a pivotal year for AI emergence [3] - It highlights a nationwide AI practical course organized by 混沌, aimed at helping businesses implement AI effectively [4] Group 1: Target Audience - The course is designed for various stakeholders including CEOs, business leaders, entrepreneurs, and 混沌 alumni who seek to leverage AI for efficiency and competitive advantage [5] Group 2: Course Highlights - The course features over 200 real-world AI case studies from diverse industries such as manufacturing, retail, education, internet, and healthcare, showcasing practical applications of AI [5] - Attendees will have the opportunity to hear from successful entrepreneurs in the AI field who will share insights and experiences from their own companies [6] - Participants can engage in workshops where they can receive free consultations from 50 AI coaches, aimed at developing actionable AI solutions [13] - The event includes an AI innovation market where attendees can experience AI products and network with industry peers for potential collaborations and investments [13] - A special tour to 海澜之家’s intelligent supply chain base will be available, providing insights into how traditional businesses are integrating AI into their operations [14]

Group 1 - The recent surge in A-share companies planning to list in Hong Kong, with 25 companies announcing plans since September and 76 others awaiting hearings as of October 2 [1][3] - Active participation from pharmaceutical companies such as Kexing Pharmaceutical, Newway, and Borui Pharmaceutical, alongside firms from various sectors like automotive and consumer goods [3] - The "A+H" dual listing model has become increasingly significant, with 11 A-share companies completing "A+H" listings this year, raising a total of 916.89 billion HKD [3] Group 2 - Notable fundraising amounts from five companies: Ningde Times (410.06 billion HKD), Heng Rui Pharmaceutical (113.74 billion HKD), Sanhua Intelligent Control (107.36 billion HKD), Haitian Flavoring and Food (105.71 billion HKD), and Lens Technology (54.83 billion HKD), collectively accounting for over 50% of this year's total IPO financing in Hong Kong [3] - The total financing amount for Hong Kong stocks reached 1,345 billion HKD by the end of August, marking a nearly sixfold increase compared to the same period in 2024 [3] - The "A+H" model accounted for 70% of the total fundraising in the first half of the year, highlighting the dynamic interconnection between the Shanghai, Shenzhen, and Hong Kong markets [3]

Group 1 - The report highlights that Chinese "manufacturing hard consumption" companies are entering a golden development period for globalization, transitioning from "product export" to "brand export" due to technological accumulation, supply chain advantages, and global layout [1][2] - The Chinese government has introduced favorable policies to support the globalization of manufacturing hard consumption enterprises, including guidance on brand internationalization and cross-border trade facilitation [2][3] - In 2024, policy support will focus on cross-border e-commerce and overseas warehouse construction, addressing challenges in overseas storage and distribution for enterprises [3][4] Group 2 - Chinese manufacturing hard consumption enterprises have developed a multi-faceted overseas expansion model characterized by "technological breakthroughs, localized production, and brand upgrades," with significant global factory layouts [3][4] - The innovation capabilities of Chinese companies in the consumer electronics and smart hardware sectors are gaining global recognition, with products like robotic vacuum cleaners and portable chargers consistently ranking as best sellers on cross-border e-commerce platforms [4][5] - The report identifies three major opportunities for the globalization of Chinese manufacturing hard consumption during the 15th Five-Year Plan period: the release of demand in emerging markets, product premiumization driven by technological upgrades, and the improvement of cross-border e-commerce and overseas warehouse systems [5][6] Group 3 - The globalization of Chinese manufacturing hard consumption is evolving from simple "product output" to "standard output" and "service output," with companies participating in the formulation of global industry standards and establishing comprehensive after-sales service networks [5][6] - The report emphasizes that the globalization journey of Chinese manufacturing hard consumption enterprises has entered a new phase, supported by policies, industrial foundations, and innovation vitality, positioning them as key players in the global consumption market [6][7] - The report outlines a comprehensive policy framework to support the internationalization of the domestic consumption industry, facilitating the transition from "product export" to "capacity export" and "brand export" [24][25]